Chromosomal instability detected by interphase fluorescence in situ hybridization and its relation to p53 alteration in prostate carcinoma in Saudi patients

Saudi Medical Journal

Volumn 26, Issue 3, 2005, Pages 379-384

  Al Maghrabi, Jaudah A ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CANADA; CENTROMERE; CHROMOSOMAL INSTABILITY; CHROMOSOME 7; CHROMOSOME 8; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PROSTATE CARCINOMA; SAUDI ARABIA;

CHROMOSOMAL INSTABILITY; GENES, P53; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PROSTATIC NEOPLASMS;

EID: 17844407883     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Al-Maghrabi J, Vorobyova L, Chapman W, Jewett M, Zielenska M, Squire JA. p53 alteration and chromosomal instability in prostatic high-grade intraepithelial neoplasia and concurrent carcinoma: analysis by immunohistochemistry, interphase in situ hybridization, and sequencing of laser-captured microdissected specimens. Mod Pathol 2001; 14: 1252-1262.
2. Al-Maghrabi J, Vorobyova L, Toi A, Chapman W, Zielenska M, Squire JA. Identification of numerical chromosomal changes detected by interphase fluorescence in situ hybridization in high-grade prostate intraepithelial neoplsaia as a predictor of carcinoma. Arch Pathol Lab Med 2002; 126: 165-169.
3. Vukovic B, Park PC, Al-Maghrabi J, Beheshti B, Sweet J, Evans A, et al. Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma. Oncogene 2003; 22: 1978-1987.
4. Tamboli P, Amin MB, Xu HJ, Linden MD. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate. Mod Pathol 1998; 11: 247-252.
5. Gumerlock PH, Chi SG, Shi XB, Voeller HJ, Jacobson JW, Gelmann EP, et al. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. J Natl Cancer Inst 1997; 89: 66-71.
6. Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, Srivastava S. The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? Urology 1996; 48: 971-979.
7. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993; 85: 1657-1669.
8. Thomas DJ, Robinson M, King P, Hasan T, Charlton R, Martin J, et al. p53 expression and clinical outcome in prostate cancer. Br J Urol 1993; 72: 778-781.
9. Yasunaga Y, Shin M, Fujita MQ, Nonomura N, Miki T, Okuyama A, et al. Different patterns of p53 mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of microdissected specimens. Lab Invest 1998; 78: 1275-1279.
10. Salem CE, Tomasic NA, Elmajian DA, Esrig D, Nichols PW, Taylor CR, et al. p53 protein and gene alterations in pathological stage C prostate carcinoma [see comments]. J Urol 1997; 158: 510-514.
11. Massenkeil G, Oberhuber H, Hailemariam S, Sulser T, Diener PA, Bannwart F, et al. P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer. Anticancer Res 1994; 14: 2785-2790.
12. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, et al. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 1999; 161: 304-308.
13. Stricker HJ, Jay JK, Linden MD, Tamboli P, Amin MB. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Urology 1996; 47: 366-369.
14. Cheng L, Leibovich BC, Bergstralh EJ, Scherer BG, Pacelli A, Ramnani DM, et al. p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression? Cancer 1999; 85: 2455-2459.
15. Meyers FJ, Gumerlock PH, Chi SG, Borchers H, Deitch AD, deVere White RW. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 1998; 83: 2534-2539.
16. Mirchandani D, Zheng J, Miller GJ, Ghosh AK, Shibata DK, Cote RJ, et al. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995; 147: 92-101.
17. MacGrogan D, Bookstein R. Tumour suppressor genes in prostate cancer. Semin Cancer Biol 1997; 8: 11-19.
18. Veltman JA, Bot FJ, Huynen FC, Ramaekers FC, Manni JJ, Hopman AH. Chromosome instability as an indicator of malignant progression in laryngeal mucosa. J Clin Oncol 2000; 18: 1644-1651.
19. Veltman JA, Hopman AH, van der Vlies SA, Bot FJ, Ramaekers FC, Manni JJ. Double-target fluorescence in situ hybridization distinguishes multiple genetically aberrant clones in head and neck squamous cell carcinoma. Cytometry 1998; 34: 113-120.
20. Rabinovitch PS, Dziadon S, Brentnall TA, Emond MJ, Crispin DA, Haggitt RC, et al. Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer Res 1999; 59: 5148-5153.
21. Ried T, Heselmeyer-Haddad K, Blegen H, Schrock E, Auer G. Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Genes Chromosomes Cancer 1999; 25: 195-204.
22. Burt EC, James LA, Greaves MJ, Birch JM, Boyle JM, Varley JM. Genomic alterations associated with loss of heterozygosity for TP53 in Li-Fraumeni syndrome fibroblasts. Br J Cancer 2000; 83: 467-472.
23. Hawkins NJ, Gorman P, Tomlinson IP, Bullpitt P, Ward RL. Colorectal carcinomas arising in the hyperplastic polyposis syndrome progress through the chromosomal instability pathway. Am J Pathol 2000; 157: 385-392.
24. Shackney SE, Shankey TV. Common patterns of genetic evolution in human solid tumors. Cytometry 1997; 29: 1-27.
25. Williams AC, Miller JC, Collard T, Browne SJ, Newbold RF, Paraskeva C. The effect of different TP53 mutations on the chromosomal stability of a human colonic adenoma derived cell line with endogenous wild type TP53 activity, before and after DNA damage. Genes Chromosomes Cancer 1997; 20: 44-52.
26. Yasui W, Yokozaki H, Fujimoto J, Naka K, Kuniyasu H, Tahara E. Genetic and epigenetic alterations in multistep carcinogenesis of the stomach. J Gastroenterol 2000; 35: 111-115.
27. Tarapore P, Fukasawa K. p53 mutation and mitotic infidelity. Cancer Invest 2000; 18: 148-155.
28. Kirchhoff M, Rose H, Petersen BL, Maahr J, Gerdes T, Lundsteen C, et al. Comparative genomic hybridization reveals a recurrent pattern of chromosomal aberrations in severe dysplasia/carcinoma in situ of the cervix and in advanced-stage cervical carcinoma. Genes Chromosomes Cancer 1999; 24: 144-150.
29. Mian C, Bancher D, Kohlberger P, Kainz C, Haitel A, Czer K, et al. Fluorescence in situ hybridization in cervical smears: detection of numerical aberrations of chromosomes 7, 3, and X and relationship to HPV infection. Gynecol Oncol 1999; 75: 41-46.
30. Aubele M, Zitzelsberger H, Schenck U, Walch A, Hofler H, Werner M. Distinct cytogenetic alterations in squamous intraepithelial lesions of the cervix revealed by laser-assisted microdissection and comparative genomic hybridization. Cancer 1998; 84: 375-379.
31. Henke RP, Kruger E, Ayhan N, Hubner D, Hammerer P. Frequency and distribution of numerical chromosomal aberrations in prostatic cancer. Hum Pathol 1994; 25: 476-484.
32. Qian J, Bostwick DG, Takahashi S, Borell TJ, Brown JA, Lieber MM, et al. Comparison of fluorescence in situ hybridization analysis of isolated nuclei and routine histological sections from paraffin-embedded prostatic adenocarcinoma specimens. Am J Pathol 1996; 149: 1193-1199.
33. Erbersdobler A, Bardenhagen P, Henke RP. Numerical chromosomal anomalies in latent adenocarcinomas of the prostate. Prostate 1999; 38: 92-99.
34. Erbersdobler A, Gurses N, Henke RP. Numerical chromosomal changes in high-grade prostatic intraepithelial neoplasia (PIN) and concomitant invasive carcinoma. Pathol Res Pract 1996; 192: 418-427.
35. Aubele M, Zitzelsberger H, Szucs S, Werner M, Braselmann H, Hutzler P, et al. Comparative FISH analysis of numerical chromosome 7 abnormalities in 5- micron and 15-micron paraffin-embedded tissue sections from prostatic carcinoma. Histochem Cell Biol 1997; 107: 121-126.
36. Mosli HA. Prostate cancer in Saudi Arabia in 2002. Saudi Med J 2003; 24: 573-581.
37. Mosli HA. Incidental Adenocarcinoma of the Prostate: Frequency Rate at a Tertiary Care Hospital. Ann Saudi Med 1997; 17: 662-664.
38. Mosli HA. Prostate Cancer: Experience at King Abdulaziz University Hospital, Jeddah. Ann Saudi Med 1997; 17: 590-594.
39. Mosli HA. Prostate Cancer in Saudi Arabia, Review of the literature (1975-1996). Ann Saudi Med 1997; 17: 510-514.
40. Kamal BA AG, Taha SA. Prostate specific antigen reference ranges in Saudi men. Saudi Med J 2003; 24: 665-668.
41. Hanash KA UD, Cook EN, Taylor WF, Titus JL. Carcinoma of the prostate: A 15-year follow-up. J Urol 1972; 107: 450-453.
42. National Cancer Registry. Cancer Incidence in Saudi Arabia 1997-1998 Report. Kingdom of Saudi Arabia: Ministry of Health: 2001. p. 40-41.
43. Yang G, Stapleton AM, Wheeler TM, Truong LD, Timme TL, Scardino PT, et al. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res 1996; 2: 399-401.
44. Ruijter E, van de Kaa C, Aalders T, Ruiter D, Miller G, Debruyne F, et al. Heterogeneous expression of E-cadherin and p53 in prostate cancer: clinical implications. BIOMED-II Markers for Prostate Cancer Study Group. Mod Pathol 1998; 11: 276-281.
45. Schlechte HH, Schnorr D, Loning T, Rudolph BD, Pohrt UM, Loening SA. Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers - investigation by temperature gradient gel electrophoresis (TGGE). J Urol 1997; 157: 1049-1053.
46. Stattin P, Bergh A, Karlberg L, Nordgren H, Damber JE. p53 immunoreactivity as prognostic marker for cancer-specific survival in prostate cancer. Eur Urol 1996; 30: 65-72.
47. Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, von Eschenbach AC, et al. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 1995; 45: 470-475.
48. Wertz IE, Deitch AD, Gumerlock PH, Gandour-Edwards R, Chi SG, de Vere White RW. Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Hum Pathol 1996; 27: 573-580.
49. Jacquemier J, Moles JP, Penault-Llorca F, Adelaide J, Torrente M, Viens P, et al. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer 1994; 69: 846-852.
50. Zeng L RR, Lele SM, Kyprianou N. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. Hum Pathol 2004; 35: 290-297.
51. Yin XY, Grove L, Datta NS, Long MW, Prochownik EV. C-myc overexpression and p53 loss cooperate to promote genomic instability. Oncogene 1999; 18: 1177-1184.
52. Kanekawa A, Tsuji T, Oga A, Sasaki K, Shinozaki F. Chromosome 17 abnormalities in squamous cell carcinoma of the oral cavity, and its relationship with p53 and Bcl-2 expression. Anticancer Res 1999; 19: 81-86.
53. Eshleman JR, Casey G, Kochera ME, Sedwick WD, Swinler SE, Veigl ML, et al. Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53. Oncogene 1998; 17: 719-725.
54. Kohno H, Hiroshima K, Toyozaki T, Fujisawa T, Ohwada H. p53 mutation and allelic loss of chromosome 3p, 9p of preneoplastic lesions in patients with nonsmall cell lung carcinoma. Cancer 1999; 85: 341-347.
55. Albertoni M, Daub DM, Arden KC, Viars CS, Powell C, Van Meir EG. Genetic instability leads to loss of both p53 alleles in a human glioblastoma. Oncogene 1998; 16: 321-326.
56. Carroll PE, Okuda M, Horn HF, Biddinger P, Stambrook PJ, Gleich LL, et al. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 1999; 18: 1935-1944.
57. Fukasawa K, Wiener F, Vande Woude GF, Mai S. Genomic instability and apoptosis are frequent in p53 deficient young mice. Oncogene 1997; 15: 1295-1302.
58. Agapova LS, Ilyinskaya GV, Turovets NA, Ivanov AV, Chumakov PM, Kopnin BP. Chromosome changes caused by alterations of p53 expression. Mutat Res 1996; 354: 129-138.
59. Smith ML, Fornace AJ, Jr. Genomic instability and the role of p53 mutations in cancer cells. Curr Opin Oncol 1995; 7: 69-75.
60. Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi YP, Pinkel D, et al. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev 1995; 9: 882-895.
61. Bouffler SD, Kemp CJ, Balmain A, Cox R. Spontaneous and ionizing radiation-induced chromosomal abnormalities in p53-deficient mice. Cancer Res 1995; 55: 3883-3889.
62. Lingle WL, Lutz WH, Ingle JN, Maihle NJ, Salisbury JL. Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. Proc Natl Acad Sci U S A 1998; 95: 2950-2955.
63. Pihan GA, Purohit A, Wallace J, Knecht H, Woda B, Quesenberry P, et al. Centrosome defects and genetic instability in malignant tumors. Cancer Res 1998; 58: 3974-3985.
64. Ghadimi BM, Sackett DL, Difilippantonio MJ, Schrock E, Neumann T, Jauho A, et al. Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. Genes Chromosomes Cancer 2000; 27: 183-90.
65. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF. Abnormal centrosome amplification in the absence of p53. Science 1996; 271: 1744-1747.
66. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386: 623-627.
67. Karashima T, Taguchi T, Yoshikawa C, Kamada M, Kasahara K, Yuri K, et al. Numerical chromosomal changes in metastatic prostate cancer following anti-androgen therapy: fluorescence in situ hybridization analysis of 5 Japanese cases. Cancer Genet Cytogenet 2000; 120: 148-154.
68. Qian J, Jenkins RB, Bostwick DG. Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. Mod Pathol 1997; 10: 1113-1119.